Heather Whitson
speaker
81 appearances
1 recordings
1 series
first heard Dec 2023
last heard Dec 2023
Heather Whitson’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Yeah, that's that's really what I want to stay with, is is I'm very curious, Lon and and Jason's thoughts on this.
The asymptomatic person that has, and we could even get more specific than amyloid, but has, as Jason said, pathological
Amyloid forty two A beta forty two that is perivascular and certainly looks like it's on the track to to eventually being what what we would all agree is Alzheimer's disease and that that person likely is going to develop cognitive symptoms, but they haven't now.
The the value versus the harm of labeling that person today.
with Alzheimer's disease, the same way that, you know, if I I don't have any symptoms, but if I had a colonoscopy in a couple of months and they to they determined that I had a pathological tumor, I would I would not reject the idea that I had cancer.
I would say, yes, I have cancer even though I'm not having any symptoms.
Pathology says I do.
What do you think is the the harm and the benefit of change shifting our thinking so that we would find a person that had, and right now we might have imperfect biomarkers, but let's say we had more perfect biomarkers.
Um, that could say this does look like this is.
Amyloidopathy that is consistent with what will eventually develop into Alzheimer's dementia.
Would you would you still reject the idea of calling those people Alzheimer's disease before they have symptoms?
I I think we have an obligation to do that.
I I think that it's premature to push out a new revised framework.
And I say that as a person that probably at at least I think I'm in a different part of the spectrum than Lon.
I'm not quite sure yet where Jason is, but
I'm I'm more accepting of the idea that
so that that if we had a perfect biomarker for the kind of amyloidopathy that normally leads to Alzheimer's disease, I would be okay calling that Alzheimer's disease from a scientific standpoint in people who don't yet have symptoms.
And I could see
benefits to doing that for being able to target therapies if we had
therapies and develop therapies that would be better.
Showing 21–40 of 81 · page 2 of 5
← Previous
Next →